Cetuximab

• A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended
  2023-509405-77-00 Phase III 13 countries Pfizer Inc.
• Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended
  2024-513964-24-00 Phase III 1 country Groupe Oncologie Radiotherapie Tete Cou
• A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KR… Ended
  2024-516699-14-00 Phase I (FiH) 5 countries AstraZeneca AB
• Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after fi… Ended
  2023-505356-22-00 Phase II 1 country Gruppo Oncologico Del Nord Ovest
• Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien… Ended
  2022-502584-38-00 Phase III 1 country Groupe Oncologie Radiotherapie Tete Cou
• Oral fluorescent tracer administration to detect of early esophageal adenocarcinomas Ended
  2023-503801-12-00 Phase II 1 country University Medical Center Groningen
• ZN-c3 in Adult Participants With Metastatic Colorectal Cancer Ended
  2022-502267-37-00 Phase I/II 5 countries K-Group Beta Inc.
• A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects Wi… Ended
  2022-501618-70-00 Phase I (FiH) 4 countries C4 Therapeutics Inc.
• A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination w… Ended
  2022-501451-87-00 Phase I/II 3 countries Zhejiang Genfleet Therapeutics Co. Ltd.
• A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetux… Ended
  2024-513082-39-00 Phase II 3 countries Nanobiotix
• Study of Monalizumab Given With Cetuximab or Placebo Given with Cetuximab in Patients With Head and Neck Cancer that has come back or spread… Ended
  2024-511813-39-00 Phase III 1 country AstraZeneca AB
• Study to evaluate the efficacy and safety of cetuximab plus irinotecan compared to investigator's choice therapy in patients with metastatic… Ended
  2024-518728-59-00 Phase II 1 country Associacio Per A La Recerca Oncologica
• MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY … Ended
  2024-517362-41-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
• A Phase 3 randomized clinical Study of Pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen as first line trea… Ended
  2024-512015-47-00 Phase III 2 countries Incyte Corp.
• Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors Ended
  2023-505070-15-00 Phase I/II 5 countries Bristol-Myers Squibb Services Unlimited Company
• Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlle… Ended
  2025-520735-16-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale

Showing 49–64 of 64 trials